



CIN No. : L24239DL2004PLC125888

## **AKUMS DRUGS & PHARMACEUTICALS LIMITED**

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

---

Ref: Akums/Exchange/2024-25/66

February 14, 2025

**To,  
The Listing Department  
National Stock Exchange of India Ltd  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051**

**To,  
The Listing Department  
BSE Limited  
Rotunda Building, Phiroze  
Jeejeebhoy Towers, Dalal  
Street, Fort, Mumbai - 400 001**

**Symbol: AKUMS**

**Scrip Code: 544222**

**Sub: Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of Patent**

Respected Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that The Patent Office, Government of India, has granted Patent to the Company on February 13, 2025 for its invention entitled "**BENZALKONIUM CHLORIDE FREE OPHTHALMIC FORMULATION**" vide patent no. 560288, valid for a term of 20 years in accordance with the provisions of the Patents Act, 1970.

Akums Drugs and Pharmaceuticals Limited, one of India's leading Contract Development and Manufacturing Organizations (CDMO), has been awarded a patent for Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation, designed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This milestone underscores Akums commitment to innovation in ophthalmic solutions, addressing the need for safer and more patient-friendly formulations.

Open-angle glaucoma and ocular hypertension are progressive eye conditions that can lead to irreversible vision loss if left untreated. Open-angle glaucoma, the most common form, develops gradually due to impaired drainage of aqueous humor, resulting in elevated intraocular pressure (IOP) that damages the optic nerve. Ocular hypertension, a condition where IOP is higher than normal but without visible optic nerve damage, significantly increases the risk of developing glaucoma over time.

In India, glaucoma affects approximately 11.9 million people, contributing to 12.8% of blindness cases. Among adults aged 40 years and above, the prevalence of glaucoma ranges from 2.7% to 4.3%. Addressing this critical ophthalmic challenge, Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation offers a key advantage over traditional eye drops containing preservatives like benzalkonium chloride, which can cause ocular surface irritation, dryness, and discomfort with prolonged use. By eliminating Benzalkonium Chloride, this innovative formulation enhances patient comfort, making it particularly beneficial for individuals those requiring long-term glaucoma management.

This is for your kind information and record.

Thanking You

For **Akums Drugs and Pharmaceuticals Limited**

**Dharamvir Malik**  
**Company Secretary & Compliance Officer**

*Encl: As above*





क्रम सं/SL No :011218691



पेटेंट कार्यालय, भारत सरकार

The Patent Office, Government Of India

पेटेंट प्रमाण पत्र

Patent Certificate

(पेटेंट नियमावली का नियम 74)

(Rule 74 of The Patents Rules)

पेटेंट सं. / Patent No.

560208

आवेदन सं. / Application No.

202311033469

फाइल करने की तारीख / Date of Filing

11/05/2023

पेटेंटी / Patentee

Akums Drugs & Pharmaceutical Limited

प्रमाणित किया जाता है कि पेटेंटी को, उपरोक्त आवेदन में यथाप्रकटित **BENZALKONIUM CHLORIDE FREE OPHTHALMIC FORMULATION** नामक आविष्कार के लिए, पेटेंट अधिनियम, 1970 के उपबंधों के अनुसार आज तारीख मई 2023 के ग्यारहवें दिन से बीस वर्ष की अवधि के लिए पेटेंट अनुदत्त किया गया है।

It is hereby certified that a patent has been granted to the patentee for an invention entitled **BENZALKONIUM CHLORIDE FREE OPHTHALMIC FORMULATION** as disclosed in the above mentioned application for the term of 20 years from the 11<sup>th</sup> day of May 2023 in accordance with the provisions of the Patents Act, 1970.



उत्तम पांडे  
पेटेंट नियंत्रक  
Controller of Patents

अनुदान की तारीख : 13/02/2025  
Date of Grant :

टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस, यदि इसे बनाए रखा जाना है, मई 2025 के ग्यारहवें दिन को और उसके पश्चात प्रत्येक वर्ष में उसी दिन देय होगा।  
Note. - The fees for renewal of this patent, if it is to be maintained, will fall / has fallen due on 11<sup>th</sup> day of May 2025 and on the same day in every year thereafter.